Staying on Track: Life with Wet AMD
At a Glance
For wet AMD, keeping scheduled scans and injections is the most important way to limit preventable vision loss because recurrence can be silent. Smoking cessation, appropriate AREDS2 use, healthy habits, and low-vision tools can support long-term independence.
Managing wet age-related macular degeneration (wet AMD) is a marathon, not a sprint. Because the disease can reactivate without warning, your most powerful tool is adherence—the commitment to showing up for every scheduled scan and injection, even when your vision feels stable [1][2].
While the “treatment burden” of frequent visits is real, staying on schedule is the single best way to protect your independence and keep your world in focus.
Why Every Appointment Matters
It can be tempting to skip a visit if your vision hasn’t changed, but wet AMD is often “silent” in its early stages of recurrence. Research shows that:
- The Cost of Delay: Studies show that missed or prolonged treatment intervals are associated with poorer outcomes. When treatment is delayed, patients are at a higher risk of losing vision [1].
- Silent Recurrence: Even after the disease seems “quiet,” it can wake up. Recurrence after apparent quiescence supports continued scheduled surveillance, as recurrences can be entirely asymptomatic and only detected on scans [2].
- Irreversible Damage: When you delay a visit, fluid or blood can sit under the retina longer, leading to fibrosis (scarring) or atrophy (the death of retinal cells). Once these occur, injections can no longer restore the lost sight [3][4].
If You Must Delay an Appointment: We acknowledge the emotional fear, caregiver strain, and barriers of cost and transportation. If you miss an appointment, contact the clinic as soon as possible. Many clinics have social workers who can assist with transportation or patient assistance programs [5][6].
Lifestyle: Protecting Your Progress
While injections do the heavy lifting, your daily choices provide the foundation for eye health.
1. Smoking Cessation
Any current smoking increases your AMD risk, and the risk generally rises with cumulative exposure. It increases inflammation and reduces blood flow to the eye. Ask your doctor for cessation support [7][8].
2. AREDS2 Supplements
You may have heard of AREDS2 vitamins. It is important to understand what they do—and what they don’t:
- What they do: They are generally indicated for people with intermediate AMD or advanced AMD in one eye, to help slow progression [9][10].
- What they don’t: They are not a replacement for injections, do not “fix” active wet AMD, and should not be taken by everyone with wet AMD. Confirm your stage and the exact formula with your clinician [9].
- A Note for Smokers: If you are a current or former smoker, ensure your supplement does not contain beta-carotene, as this has been linked to an increased risk of lung cancer in smokers. Modern AREDS2 formulas typically use lutein and zeaxanthin instead [9].
3. Diet and Physical Activity
A heart-healthy or Mediterranean-style diet (rich in dark leafy greens and omega-3 fatty acids) provides sensible general health advice [8][11]. Regular exercise and maintaining a healthy weight also help manage the cardiovascular health that supports your vision [12]. However, no food or omega-3 supplement reverses active wet AMD or substitutes for injections.
Adapting to Daily Life
If you have already experienced some vision loss, “low vision” does not mean “no vision.” There are many tools designed to help you use your remaining vision more effectively [13].
- Magnification: Electronic magnifiers, high-powered reading glasses, and digital “video magnifiers” can make reading much easier.
- Lighting and Home Safety: Use adequate, low-glare, high-contrast lighting to reduce strain and prevent falls in the home.
- Driving: Ask your doctor to evaluate your vision and advise you on local driving regulations.
- Technology: Most smartphones and tablets have built-in accessibility features like screen readers (which read text out loud) and voice commands that allow you to text and call without needing to see the buttons [14].
- Rehabilitation: Ask your doctor for a referral to a low-vision specialist or an occupational therapist. They can teach you techniques for “eccentric viewing”—using your side vision to see things that are normally in your central blind spot [13][15].
Common questions in this guide
Why do I need wet AMD scans and injections when my vision seems stable?
What should I do if I have to miss a wet AMD appointment?
Should I take AREDS2 vitamins if I have wet AMD?
Can diet, omega-3 supplements, or exercise reverse wet AMD?
Can wet AMD come back without symptoms?
What can help me manage daily activities after wet AMD vision loss?
Get notified when new evidence is published on wet macular degeneration.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
Ramakrishnan MS, Yu Y, VanderBeek BL
JAMA ophthalmology 2020; (138(3)):237-242 doi:10.1001/jamaophthalmol.2019.4577.
PMID: 32027349 - 2
Reactivation of stable neovascular age-related macular degeneration following treat-and-extend regimen discontinuation.
Artiaga JCM, Wong SW, Menon D, et al.
Clinical & experimental ophthalmology 2025; (53(1)):76-83 doi:10.1111/ceo.14444.
PMID: 39354837 - 3
TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
Starr MR, Kung FF, Mejia CA, et al.
Retina (Philadelphia, Pa.) 2020; (40(9)):1665-1672 doi:10.1097/IAE.0000000000002668.
PMID: 31725524 - 4
Long-Term Visual Outcomes in Exudative Age-Related Macular Degeneration Patients With Unanticipated Gaps in Therapy.
Bui YT, Starr MR, Kung FF, et al.
Ophthalmic surgery, lasers & imaging retina 2022; (53(9)):481-489 doi:10.3928/23258160-20220819-02.
PMID: 36107628 - 5
Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration.
Loewenstein A, Sylvanowicz M, Amoaku WM, et al.
Ophthalmology and therapy 2025; (14(1)):211-228 doi:10.1007/s40123-024-01061-3.
PMID: 39673040 - 6
Barriers to care in neovascular age-related macular degeneration: Current understanding, developments, and future directions.
Choi A, Nawash BS, Du K, et al.
Survey of ophthalmology 2024; (69(1)):160-164 doi:10.1016/j.survophthal.2023.09.001.
PMID: 37716480 - 7
Age-Related Macular Degeneration: A Review.
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U
JAMA 2024; (331(2)):147-157 doi:10.1001/jama.2023.26074.
PMID: 38193957 - 8
Age-related macular degeneration.
Mitchell P, Liew G, Gopinath B, Wong TY
Lancet (London, England) 2018; (392(10153)):1147-1159 doi:10.1016/S0140-6736(18)31550-2.
PMID: 30303083 - 9
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Evans JR, Lawrenson JG
The Cochrane database of systematic reviews 2017; (7()):CD000254 doi:10.1002/14651858.CD000254.pub4.
PMID: 28756618 - 10
Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020.
Samanta A, Aziz AA, Jhingan M, et al.
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2021; (10(4)):408-416 doi:10.1097/APO.0000000000000355.
PMID: 33512911 - 11
Recent developments in the management of dry age-related macular degeneration.
Buschini E, Fea AM, Lavia CA, et al.
Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):563-74 doi:10.2147/OPTH.S59724.
PMID: 25878491 - 12
Mechanistic Insight into Age-Related Macular Degeneration (AMD): Anatomy, Epidemiology, Genetics, Pathogenesis, Prevention, Implications, and Treatment Strategies to Pace AMD Management.
Amini MA, Karbasi A, Vahabirad M, et al.
Chonnam medical journal 2023; (59(3)):143-159 doi:10.4068/cmj.2023.59.3.143.
PMID: 37840684 - 13
Japanese clinical guidelines for neovascular age-related macular degeneration.
Iida T, Gomi F, Yasukawa T, et al.
Japanese journal of ophthalmology 2025; (69(4)):639-660 doi:10.1007/s10384-025-01240-0.
PMID: 40658332 - 14
Impact of living with a bilateral central vision loss due to geographic atrophy-qualitative study.
Madheswaran G, Ramesh SV, Pardhan S, et al.
BMJ open 2021; (11(7)):e047861 doi:10.1136/bmjopen-2020-047861.
PMID: 34326049 - 15
Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.
Agarwal A, Rhoades WR, Hanout M, et al.
Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):1001-15 doi:10.2147/OPTH.S74959.
PMID: 26089632
This page provides educational information about living with wet AMD and staying on schedule with care; it does not replace medical advice. Ask your eye-care team before changing injections, supplements, or other parts of your treatment plan.